PMID- 17345065
OWN - NLM
STAT- MEDLINE
DCOM- 20070806
LR  - 20220716
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 192
IP  - 4
DP  - 2007 Jul
TI  - Ethanol-MDMA interactions in rats: the importance of interval between repeated 
      treatments in biobehavioral tolerance and sensitization to the combination.
PG  - 555-69
AB  - RATIONALE: In our previous work, we showed that ethanol (EtOH) potentiates 
      3,4-methylenedioxymethamphetamine (MDMA)-induced hyperlocomotion while protecting 
      against its hyperthermic effects. Whereas the effect on activity were found on 
      all days (although declining over the three first days), the protection against 
      hyperthermia completely disappeared on the second day. The latter effect was 
      previously thought to reflect tolerance to ethanol or the combination, per se. 
      OBJECTIVE: In the present study, we changed the treatment regimen to irregular 
      and longer intervals between treatments (48, 120, and again 48 h) to check if 
      tolerance was still observed. RESULTS: We found progressive sensitization of 
      locomotor activity to EtOH (1.5 g/kg, i.p.)+MDMA (6.6 mg/kg, i.p.), and a partial 
      EtOH protection against MDMA-induced hyperthermia that persisted after the first 
      drug challenge day. When the monoamine neurotransmitters, dopamine, and serotonin 
      were assessed 2 weeks after treatment, we found no consistent effect on the 
      concentration of any of these neurotransmitters, whatever the treatment. 
      Similarly, we found that regional brain concentrations of MDMA were not 
      significantly affected by EtOH at a 45-min post-treatment delay; however, the 
      overall ratio of the metabolite 3,4-methylenedioxyamphetamine (MDA) to MDMA was 
      lower (overall, -16%) in animals treated with the combination compared to MDMA 
      alone, indicating possible contribution of pharmacokinetic factors. This 
      difference was especially marked in the striatum (-25%). CONCLUSIONS: These 
      findings shed new light on the consequences of EtOH-MDMA, taken together at a 
      nearly normal ambient temperature, both in terms of motivation and potential 
      risks for recreational drug users.
FAU - Ben Hamida, Sami
AU  - Ben Hamida S
AD  - LINC-UMR 7191, Universite Louis Pasteur-CNRS, Institut Federeratif de Recherche 
      37, GDR CNRS 2905, Strasbourg, France.
FAU - Plute, Erin
AU  - Plute E
FAU - Bach, Sonia
AU  - Bach S
FAU - Lazarus, Christine
AU  - Lazarus C
FAU - Tracqui, Antoine
AU  - Tracqui A
FAU - Kelche, Christian
AU  - Kelche C
FAU - de Vasconcelos, Anne Pereira
AU  - de Vasconcelos AP
FAU - Jones, Byron C
AU  - Jones BC
FAU - Cassel, Jean-Christophe
AU  - Cassel JC
LA  - eng
PT  - Journal Article
DEP - 20070308
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Biogenic Monoamines)
RN  - 0 (Central Nervous System Depressants)
RN  - 0 (Hallucinogens)
RN  - 3K9958V90M (Ethanol)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/pharmacology
MH  - Animals
MH  - Biogenic Monoamines/metabolism
MH  - Body Temperature/*drug effects
MH  - Brain/drug effects/metabolism
MH  - Central Nervous System Depressants/*pharmacology
MH  - Drug Interactions
MH  - Drug Tolerance
MH  - Ethanol/*pharmacology
MH  - Hallucinogens/*pharmacology
MH  - Male
MH  - Motor Activity/*drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Rats
MH  - Rats, Long-Evans
EDAT- 2007/03/09 09:00
MHDA- 2007/08/07 09:00
CRDT- 2007/03/09 09:00
PHST- 2006/10/20 00:00 [received]
PHST- 2007/02/19 00:00 [accepted]
PHST- 2007/03/09 09:00 [pubmed]
PHST- 2007/08/07 09:00 [medline]
PHST- 2007/03/09 09:00 [entrez]
AID - 10.1007/s00213-007-0752-9 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2007 Jul;192(4):555-69. doi: 
      10.1007/s00213-007-0752-9. Epub 2007 Mar 8.